SEATTLE--(BUSINESS WIRE)--Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs, announced promising new data demonstrating that KIN 1148 enhances the efficacy of existing influenza vaccines in animal models through a balanced immune response. Additionally, enhanced effectiveness with KIN 1148 was achieved while using lower vaccine doses. Kineta’s vaccine adjuvants are small molecule compounds added to a vaccine to improve the body’s vaccine immune response. The data were presented by Dr. Kristin Bedard, Kineta’s Vice President of Research and Development, during a presentation at the 16th Annual World Vaccine Congress in Washington, DC.
